 P27A study is designed as a randomized phase IaIb trial to evaluate the safety and immunogenicity of the blood stage candidate vaccine P27A against P. falciparum - P27A antigen and associated adjuvant Alhydrogel or GLA-SE - in malaria non exposed European volunteersSwitzerland; phase Ia and malaria exposed African volunteers Tanzania; phase Ib. 